MORU Asset Management
VC Fund
Yeoksamdong, South Korea
MORU Asset Management is a financial and asset management service provider company.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries MORU Asset Management invests in
HospitalElectronicsHealth CareBiotechnologyPharmaceutical
Stages MORU Asset Management invests in
Series ASeries BVenture - Series Unknown
Countries MORU Asset Management invests in
South Korea
Investment Focus
Industry
- Hospital 1 (33%)
- Electronics 1 (33%)
- Health Care 1 (33%)
- Biotechnology 1 (33%)
- Pharmaceutical 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
- Venture - Series Unknown 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Oncocross is a Biopharmaceutical Company. | $11M / Venture - Series Unknown / Nov 13, 2023 | ||
| Our company, Sky Labs, is developing a ring-type Cardio Tracker, CART to help continuous monitoring of atrial fibrillation which is difficult to diagnose even in a hospital in daily life.According to a disease statistics study released in 2004, atrial fibrillation is a very common chronic disease that occurs in 1 out of 4 people in their 40s orolder. As stated in the Atrial Fibrillation Report from the UK's Atrial Fibrillation Association in 2012, the biggest problem is that atrial fibrillation is not diagnosed in 1 in 2 patients because it is not accompanied by severe subjective symptoms and hard to find due to the intermittent properties.To diagnose atrial fibrillation, the following three features of continuous monitoring are essential. Our product, CART, is equipped with these features to fully maximize the benefits of continuous monitoring.1) Comfortability as a wearable device : You can always wear CART on a daily basis. Additionally, it is even water-proof and dust-proof. So, you don't have to take it off while taking a shower, or washing hands.2) No-user intervention : By just wearing it on any finger which fits for you, every measurement is performed on the background basis without any intervention.3) Medical proof & Accuracy : Diagnosis is based on the conventional diagnosis method of cardiologists.By simply wearing CART on user's finger, CART continuously detects atrial fibrillation without any user intervention. CART detects and records atrial fibrillation, so users can track and manage their heart health status. In addition, users can diagnose atrial fibrillation whenever they want and see the results on their smartphone. By merely tapping CART, users can make event logs and analyze atrial fibrillation data at that moment when it occurs. Finally, the collected atrial fibrillation data can be used to help the physician diagnose of the atrial fibrillation.Initial target market is 0.2 million atrial fibrillation patients in Finland. Total target market is 300 million people to diagnose atrial fibrillation and tens of million subjects in clinical trials.Sky Labs is currently conducting clinical trials with the Seoul National University Hospital to verify the device's performance and is analyzing clinical data on heart disease. And, Sky Labs is working with global pharmaceutical company Bayer to make innovative healthcare business. | $20M / Series B / Jun 22, 2021 | ||
| Our company, Sky Labs, is developing a ring-type Cardio Tracker, CART to help continuous monitoring of atrial fibrillation which is difficult to diagnose even in a hospital in daily life.According to a disease statistics study released in 2004, atrial fibrillation is a very common chronic disease that occurs in 1 out of 4 people in their 40s orolder. As stated in the Atrial Fibrillation Report from the UK's Atrial Fibrillation Association in 2012, the biggest problem is that atrial fibrillation is not diagnosed in 1 in 2 patients because it is not accompanied by severe subjective symptoms and hard to find due to the intermittent properties.To diagnose atrial fibrillation, the following three features of continuous monitoring are essential. Our product, CART, is equipped with these features to fully maximize the benefits of continuous monitoring.1) Comfortability as a wearable device : You can always wear CART on a daily basis. Additionally, it is even water-proof and dust-proof. So, you don't have to take it off while taking a shower, or washing hands.2) No-user intervention : By just wearing it on any finger which fits for you, every measurement is performed on the background basis without any intervention.3) Medical proof & Accuracy : Diagnosis is based on the conventional diagnosis method of cardiologists.By simply wearing CART on user's finger, CART continuously detects atrial fibrillation without any user intervention. CART detects and records atrial fibrillation, so users can track and manage their heart health status. In addition, users can diagnose atrial fibrillation whenever they want and see the results on their smartphone. By merely tapping CART, users can make event logs and analyze atrial fibrillation data at that moment when it occurs. Finally, the collected atrial fibrillation data can be used to help the physician diagnose of the atrial fibrillation.Initial target market is 0.2 million atrial fibrillation patients in Finland. Total target market is 300 million people to diagnose atrial fibrillation and tens of million subjects in clinical trials.Sky Labs is currently conducting clinical trials with the Seoul National University Hospital to verify the device's performance and is analyzing clinical data on heart disease. And, Sky Labs is working with global pharmaceutical company Bayer to make innovative healthcare business. | $4.2M / Series A / Oct 16, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Hardware Investors
40,144 investors
Consumer Investors
32,380 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Health Care VC Funds
32,370 investors
Hardware VC Funds
30,945 investors
Consumer VC Funds
23,718 investors
Biotech VC Funds
18,864 investors
FAQ
What does MORU Asset Management invest in?
MORU Asset Management invests primarily in Hospital, Electronics and Health Care startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did MORU Asset Management last invest?
The most recent investment recorded for MORU Asset Management closed in Nov 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
